12.11.23
Health Canada has approved ten unique claims which can be used on Cargill’s EpiCor postbiotic as a natural health product, related to its role in supporting immune health, digestive health, and more.
The licensed claims, supported by over one dozen studies, will help to differentiate EpiCor from other postbiotic ingredients on the market.
EpiCor’s claims, which are based on an efficacious dose of 500 mg daily for adults 18 and older, include:
“Immune and gut health remain priorities for consumers, who are looking for research-backed solutions that can positively impact their daily lives,” said Justin Green, PhD, director of scientific affairs for EpiCor. “This news, from one of the world’s leading health agencies, affirms the significant body of science behind EpiCor, highlighting its safety and lending additional credibility to its functional role supporting consumers’ health and wellness goals.”
“As a leader in postbiotic technology, we continue to invest in research and innovation in this space, with the aim of helping consumers live more healthy days,” Green said. “Receiving this authorization from Health Canada underscores the importance of this work, as we continue to expand our understanding of the health benefits afforded by our postbiotic technology.”
The licensed claims, supported by over one dozen studies, will help to differentiate EpiCor from other postbiotic ingredients on the market.
EpiCor’s claims, which are based on an efficacious dose of 500 mg daily for adults 18 and older, include:
- Helps to reduce the incidence of cold and flu symptoms (during the winter months).
- Helps to reduce the symptoms of seasonal allergies such as nasal stuffiness/congestion.
- Helps relieve nasal stuffiness/congestion associated with seasonal allergies.
- Helps to maintain immune function.
- An antioxidant that helps to support good health.
- Source of antioxidant(s)/provides antioxidant(s).
- Helps support intestinal/gastrointestinal health.
- Helps to improve occasional mild to moderate bloating/distension.
- Helps to improve occasional mild to moderate feeling of fullness.
- Occasionally helps to improve stool consistency.
“Immune and gut health remain priorities for consumers, who are looking for research-backed solutions that can positively impact their daily lives,” said Justin Green, PhD, director of scientific affairs for EpiCor. “This news, from one of the world’s leading health agencies, affirms the significant body of science behind EpiCor, highlighting its safety and lending additional credibility to its functional role supporting consumers’ health and wellness goals.”
“As a leader in postbiotic technology, we continue to invest in research and innovation in this space, with the aim of helping consumers live more healthy days,” Green said. “Receiving this authorization from Health Canada underscores the importance of this work, as we continue to expand our understanding of the health benefits afforded by our postbiotic technology.”
